The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a ...

Anne Wojcicki, co-founder and former CEO of 23andMe, has bid to buy back the genetic testing platform, which was pronounced ...

AndMe had “inadequate” security systems and was “slow to respond” to warning signs customers’ sensitive data was at risk before the "profoundly damaging" hack, officials say.

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

The state of Texas lost its bid for a temporary restraining order to halt the proposed sale of 23andMe’s genetic data bank, ...

Genetic testing firm 23andMe has been fined £2.31 million by the UK's data protection watchdog for "serious security failings ...

the $256 million acquisition of 23andMe, and a license agreement with Hansoh for the ex-China rights to a Phase 3 GLP-1/GIP receptor agonist are among the noteworthy developments. UBS identifies ...